The Top 5 Biosimilar Articles for the Week of February 22

February 26, 2021

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of February 22, 2021.

Number 5: Coherus BioSciences reported that the FDA has accepted for review its biologics license application (BLA) for an adalimumab biosimilar (CHS-1420), but did not specify the formulation concentration.

Number 4: Frontline use of rituximab biosimilars plus chemotherapy in patients with follicular lymphoma (FL) is more costly than a regimen of obinutuzumab (Gazyva) plus chemotherapy, investigators reported, based on a decision-analytic modeling study.

Number 3: Fresenius Kabi, a Germany-based biopharmaceutical company with global operations, mapped out an ambitious biosimilar launch program as it released earnings data.

Number 2: Fresenius Kabi has launched an adalimumab injectable biosimilar (Idacio) in Canada. The launch is the second adalimumab launch in a week, right after Sandoz’ launch of Hyrimoz.

Number 1: Gary H. Lyman, MD, PhD, provides an expert overview on overcoming the challenges of discussing biosimilars with patients.

To read all of these articles and more, visit centerforbiosimilars.com.